Fexinidazole

Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

  • First-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to T. brucei gambiensein patients 6 years of age and older who weigh at least 20 kg.
  • Due to decreased efficacy observed in patients with severe second-stage HAT, fexinidazole should only be used in these patients if no other options are available.
  • This drug was developed as part of the Drugs for Neglected Diseases initiative.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 19, 2022